Heartflow

1/ In the "gold rush" of medical AI, many platforms are racing to market. But in cardiology, the difference between a "good guess" and a "clinical standard" is the depth of the data behind it.

Here is why data depth is the ultimate competitive differentiator. 👇

We’re kicking off AHA #ScientificSessions26 in Chicago, and we’re so excited to be here.

Our Chief Medical Officer, Dr. Campbell Rogers, shares what to look forward to over the next few days:
▸ Booth #711: Live Heartflow demos and Innovation Hub
▸ AHA Simulation Zone: Hands-on training workshops
▸ Sunday: Our Expert Theater* in Heart Theater 1 at p.m.
▸ Monday: New DECIDE 1-year and GAMEFILM registry data

Come see us at our booth!

*This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming.

#AHA2026 #AIinHealthcare

Firefighters protect our communities. Who’s protecting their hearts?

Our Chief Medical Officer, Dr. Campbell Rogers, shares what the BRAVEHEART registry found at TCT 2026: A large majority of firefighters with no symptoms had plaque in their coronary arteries. Once they saw their own results, most were ready to take action.

They look healthy. They feel fine. But their hearts deserve a closer look.

Thank you to Dr. Milind Parikh, every firefighter who took part, and everyone who visited us in San Diego. See you at AHA in Chicago!

CT-guided PCI matched IVUS outcomes in P4. In NAVIGATE-PCI, treatment plans changed in approximately 70% of patients after PCI Navigator review.

Our Chief Medical Officer, Campbell Rogers, MD, FACC, on what these two studies at TCT2026 means for coronary intervention.

Thank you to Dr. Carlos Collet Bortone, principal investigator of P4, and Dr. Ziad Ali, principal investigator of NAVIGATE-PCI, and to every site and patient behind this work.

See you at AHA next week.

New one-year data from the prospective DECIDE registry at AHA 2026: Heartflow Plaque Analysis changed medical management in more than half of patients, with faster, more durable LDL-C control and fewer major cardiovascular events compared to CCTA alone.